"GEICAM es el grupo líder en investigación en cáncer de mama en España, y cuenta con un reconocido prestigio tanto nacional como internacional. Está constituido por más de 700 expertos, que trabajan en más de 180 hospitales de toda España. Entre sus principales objetivos está promover la investigación, tanto clínica como básica, la formación médica continuada, y la divulgación para facilitar la información a las afectadas acerca de los tratamientos y sus efectos secundarios, y así promover su participación en ensayos clínicos. Hasta el momento GEICAM ha realizado 102 estudios en los que han participado más de 43.000 mujeres."

During the past decade, Spanish Breast Cancer Research Group (GEICAM) conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Spanish Breast Cancer Research Group (GEICAM)" #1 collaborator was "Novartis" with 2 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "Hoffmann-La Roche" with 1 trials as a collaborator and "Schering-Plough" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Spanish Breast Cancer Research Group (GEICAM)" are "Breast Cancer" (4 trials), "Neoplasm Metastasis" (3 trials) and "Breast Neoplasms" (1 trials). Many other conditions were trialed in "Spanish Breast Cancer Research Group (GEICAM)" in a lesser frequency.

Most popular intervention types in "Spanish Breast Cancer Research Group (GEICAM)" are "Drug" (5 trials). Other intervention types were less common.

The name of intervention was led by "Vinorelbine" (2 trials), "Capecitabine" (1 trials), "Gemcitabine" (1 trials), "Pamidronate" (1 trials) and "Pegylated liposomal doxorubicin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Spanish Breast Cancer Research Group (GEICAM)" are 5 trials for "Female" genders.

Currently, there are NaN active trials in "Spanish Breast Cancer Research Group (GEICAM)". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Spanish Breast Cancer Research Group (GEICAM), undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Spanish Breast Cancer Research Group (GEICAM), 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".